<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="publisher-id">IENZ</journal-id><journal-id journal-id-type="publisher-id">ienz20</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6882489</article-id><article-id pub-id-type="pmid">31742469</article-id><article-id pub-id-type="doi">10.1080/14756366.2019.1690481</article-id><article-id pub-id-type="publisher-id">1690481</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and <italic>in&#x000a0;vivo</italic> antihyperglycaemic efficacy</article-title><alt-title alt-title-type="running-authors">L. Yang et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lingling</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jiabao</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Junyan</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Siyan</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuanyuan</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhouyu</given-names></name><xref ref-type="aff" rid="AF0002"><sup>b</sup></xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><name><surname>Qian</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="AF0001"><sup>a</sup></xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmaceutical Engineering, College of Food and Bioengineering, Xihua University</institution>, Chengdu, <country>China</country>; </aff><aff id="AF0002"><label>b</label><institution>Department of Chemistry, College of Science, Xihua University</institution>, Chengdu, <country>China</country></aff></contrib-group><author-notes><fn id="AUFN1"><p>Supplemental data for this article can be accessed <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1690481"><underline>here</underline></ext-link>.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Shan Qian <email>qians33@163.com</email><institution>Department of Pharmaceutical Engineering, College of Food and Bioengineering, Xihua University</institution>, Chengdu 610039, <country>China</country>; </corresp><corresp id="AN0002">Zhouyu Wang <email>zhouyuwang77@gmail.com</email><institution>Department of Chemistry, College of Science, Xihua University</institution>, Chengdu 610039, <country>China</country>.</corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2019</year></pub-date><volume>35</volume><issue>1</issue><fpage seq="16">152</fpage><lpage>164</lpage><history><date date-type="received"><day>04</day><month>9</month><year>2019</year></date><date date-type="rev-recd"><day>15</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_35_1690481.pdf"/><abstract><title>Abstract</title><p>Overexpression of protein tyrosine phosphatase 1B (PTP1B) induces insulin resistance in various basic and clinical research. In our previous work, a synthetic oleanolic acid (OA) derivative <bold>C10a</bold> with PTP1B inhibitory activity has been reported. However, <bold>C10a</bold> has some pharmacological defects and cytotoxicity. Herein, a structure-based drug design approach was used based on the structure of <bold>C10a</bold> to elaborate the smaller tricyclic core. A series of tricyclic derivatives were synthesised and the compounds <bold>15</bold>, <bold>28</bold> and <bold>34</bold> exhibited the most PTP1B enzymatic inhibitory potency. In the insulin-resistant human hepatoma HepG2 cells, compound <bold>25</bold> with the moderate PTP1B inhibition and preferable pharmaceutical properties can significantly increase insulin-stimulated glucose uptake and showed the insulin resistance ameliorating effect. Moreover, <bold>25</bold> showed the improved <italic>in&#x000a0;vivo</italic> antihyperglycaemic potential in the nicotinamide&#x02013;streptozotocin-induced T2D. Our study demonstrated that these tricyclic derivatives with improved molecular architectures and antihyperglycaemic activity could be developed in the treatment of T2D.</p></abstract><abstract abstract-type="graphical"><title>Graphical Abstract</title><p><fig id="UF0001" orientation="portrait" position="anchor"><graphic content-type="color" xlink:href="IENZ_A_1690481_UF0001_C"/></fig></p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Protein tyrosine phosphatase 1B</kwd><kwd>oleanolic acid</kwd><kwd>insulin-resistant</kwd><kwd>antihyperglycaemic effect</kwd><kwd>type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">National Natural Science Foundation for the Youth of China</named-content></funding-source><award-id>81302647</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Chengdu Technology Innovation Research Project</named-content><named-content content-type="funderidentifier">10.13039/501100002790</named-content></funding-source><award-id>2018-YFYF-00195-SN</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Sichuan Science and Technology Innovation Seedling Project</named-content></funding-source><award-id>2018082</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Science and Technology Department of Sichuan Province</named-content><named-content content-type="funderidentifier">10.13039/501100004829</named-content></funding-source><award-id>2016HH0075</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">the Found of Sichuan Education Department</named-content></funding-source><award-id>18TD0023</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Open Project of School of Health Management of Xihua University</named-content></funding-source><award-id>SZJJ2017-038</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">the Innovation Fund of Xihua Scholars, Undergraduate and Post Graduate from Xihua University</named-content></funding-source></award-group><funding-statement>The project was sponsored by grants from the National Natural Science Foundation for the Youth of China (81302647), Chengdu Technology Innovation Research Project (2018-YFYF-00195-SN), Sichuan Science and Technology Innovation Seedling Project (2018082), Science and Technology Department of Sichuan Province (2016HH0075), the Found of Sichuan Education Department (18TD0023), Open Project of School of Health Management of Xihua University (SZJJ2017-038), and the Innovation Fund of Xihua Scholars, Undergraduate and Post Graduate from Xihua University.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="13"/><word-count count="8749"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>The predominant pathophysiological factor of type 2 diabetes (T2D) is insulin resistance<xref rid="CIT0001" ref-type="bibr"><sup>1&#x02013;4</sup></xref>. Though many anti-T2D drugs have emerged in the past decade<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>, traditional anti-T2D agents such as repaglinide, metformin, dipeptidyl peptidase-IV inhibitors, &#x003b1;-glucosidase inhibitors and glucagon-like peptide-1 agonists, and thiazolidinediones are still the most efficacious oral drugs in the first-line monotherapy of T2D<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>. It is undoubted that new insulin sensitisers will meet great needs of T2D patients<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref>.</p><p>Protein tyrosine phosphatase 1B (PTP1B) dephosphosphorylates the tyrosine-phosphorylated insulin receptor (IR) and the downstream insulin receptor substrate (IRS) to down regulate insulin transduction<xref rid="CIT0010" ref-type="bibr"><sup>10&#x02013;15</sup></xref>. PTP1B inhibitors could potentially improve insulin sensitivity and normalise glucose levels and therefore could be a promising therapeutic strategy in the T2D patients. Recent studies also identified the involvement of intra-islet PTP1B in the regulation of insulin release and reinforce the potential of PTP1B inhibitors for the treatment of beta-cell secretory failure in the pathogenesis of T2D<xref rid="CIT0016" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="CIT0017" ref-type="bibr"><sup>17</sup></xref>. Besides, PTP1B-mediated dephosphorylation has been implicated in the development of diabetes<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>, cancer<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>, hepatic fibrosis<xref rid="CIT0020" ref-type="bibr"><sup>20</sup></xref>, bacterial infection<xref rid="CIT0021" ref-type="bibr"><sup>21</sup></xref>, rheumatoid arthritis<xref rid="CIT0022" ref-type="bibr"><sup>22</sup></xref> and hypertension<xref rid="CIT0023" ref-type="bibr"><sup>23</sup></xref>. Many PTP1B inhibitors have been reported, but the discovery of PTP1B inhibitors with superior cell permeability and <italic>in&#x000a0;vivo</italic> potency is difficult and so far there is no PTP1B inhibitors entered III phase clinical trial<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>.</p><p>Hundreds of natural products have been isolated and identified as PTP1B inhibitors, and natural products with interesting structural diversity have potential to develop the new PTP1B inhibitors<xref rid="CIT0025" ref-type="bibr"><sup>25&#x02013;27</sup></xref>. In our previous work, some oleanolic acid (OA) derivatives with modified A-ring, C-ring, and C17 moiety were designed and synthesized<xref rid="CIT0028" ref-type="bibr"><sup>28&#x02013;33</sup></xref>. Within these OA derivatives, compound <bold>C10a</bold> (<xref ref-type="fig" rid="F0001">Figure 1</xref>) exhibited the most PTP1B inhibition (IC<sub>50</sub>: 3.12&#x02009;&#x003bc;M), which was 7.6-fold more than the parent compound OA<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>. However, the triterpenoid derivative <bold>C10a</bold> has too large molecular weight (&#x0003e;500) and some pharmacological defects, such as weak cell permeability, poor bioavailability and improper lipid/water partition coefficient. <bold>C10a</bold> also showed the considerable cytotoxicity. Therefore, the structure of <bold>C10a</bold> needs to be optimised to develop the potent PTP1B inhibitors with favourable pharmacological properties.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The chemical structures of OA and lead compound <bold>C10a</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1690481_F0001_B"/></fig><p>The structural optimisation strategy is shown in <xref ref-type="fig" rid="F0002">Figure 2</xref>. The structure of <bold>C10a</bold> contains hydrophobic scaffold, linker and aryl moiety. As displayed in <xref ref-type="fig" rid="F0003">Figure 3(A,B)</xref>, the molecular docking has demonstrated the hydrophobic interactions between the terpenoid scaffold of <bold>C10a</bold> and the surrounding amino residues of PTP1B are critical for the complex stability, but the pentacyclic core of <bold>C10a</bold> is too complicated. We assumed this scaffold could be simplified to the smaller tricyclic fragment containing the same stereo-conformation of fused A/B ring junction, such as the tricyclic terpenoid scaffold of compound <bold>15</bold> as shown in <xref ref-type="fig" rid="F0003">Figure 3(C)</xref>. One of the methyl group at 4-position also was retained, because it was beneficial for interaction with Arg24<xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>, which is an important residue at the second site of PTP1B for substrate specificity (the second site of PTP1B is a noncatalytic cleft-like binding pocket, which is not conserved among all PTPs)<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>. As shown in <xref ref-type="fig" rid="F0003">Figure 3(C)</xref>, C ring was replaced with the substituted benzene ring, which could provide opportunities to form more hydrophobic and &#x003c0;&#x02013;&#x003c0; interactions. D ring and E ring were simplified to the linker from C ring to the aryl moiety. Insertion of polar group (e.g. carboxyl, ether) into this linker would be beneficial for the favourable balance between hydrophilicity and hydrophobicity. The overlapping figure of <bold>C10a</bold> and <bold>15</bold> indicated these compounds have similar docking modes with amino residues of PTP1B (<xref ref-type="fig" rid="F0003">Figure 3(D)</xref>). Only two hydrogen-bond interactions between <bold>C10a</bold> and PTP1B were observed (Tyr46 and Lys120), so the aryl moiety of <bold>C10a</bold> was replaced with various substituted rings in order to enhance inhibition, since the aryl moiety was important for the substrate recognition<xref rid="CIT0019" ref-type="bibr"><sup>19</sup></xref>.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The structural optimisation strategy.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1690481_F0002_C"/></fig><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p><bold>C10a</bold> and <bold>15</bold> docked in the PTP1B active site (PDB ID: 2B07<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>). (A) Only the active site was shown, displaying the protein in surface representation and ligand <bold>C10a</bold> in stick representation; (B) <bold>C10a</bold>, Coloured green and displayed in stick representation, bound to these important residues in the interior of the active site. All hydrogen atoms are omitted for clarity; (C) <bold>15</bold> bound to the important residues in the interior of the active site; (D) The overlapping docking modes of <bold>C10a</bold> and <bold>15</bold>.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1690481_F0003_C"/></fig></sec><sec id="s0002"><label>2.</label><title>Results and discussion</title><sec id="s0003"><label>2.1.</label><title>Chemistry</title><p>The synthesis procedure to achieve 15-hydroxydehydroabietic acid (<bold>3</bold>) from abietic acid (AA) involved addition, elimination, and oxidation. However, according to the literatures<xref rid="CIT0036" ref-type="bibr"><sup>36&#x02013;38</sup></xref>, alcohol <bold>3</bold> was obtained in only 10% yield in our laboratory. We therefore improved the synthetic method and <bold>3</bold> was finally obtained in 70% overall yield (<xref ref-type="scheme" rid="SCH0001">Scheme 1</xref>). According to the improved synthetic procedure, AA (<bold>1</bold>) was treated with 33% HBr/AcOH and the resulting 8, 15-dibromo derivative was heated in the presence of LiOH/DMF to afford diene (<bold>2</bold>), with four methyl groups of all singlets by <sup>1</sup>HNMR. Oxidative rearrangement of <bold>2</bold> with SeO<sub>2</sub> provided 15-hydroxydehydroabietate (<bold>3</bold>) in 80% yield. <bold>3</bold> was esterified by treatment with EtI (or BnBr) to give ester <bold>4a</bold> (<bold>4&#x02009;b</bold>). <bold>4a</bold> was then reduced with LiAlH<sub>4</sub> to give alcohol <bold>5</bold>. We found 15-hydroxydehydroabietic derivatives are not suitable synthesis intermediates because of high steric hindrance of C-15 position, and thus hydroperoxide rearrangement of esters <bold>4a&#x02013;b</bold> with <italic>t</italic>-BuOOH and H<sub>2</sub>SO<sub>4</sub>/AcOH gave the 13-hydroxy-8,11,13-podocarpatriene derivatives (<bold>6a&#x02013;b</bold>)<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. Finally, ester <bold>6a</bold> was saponified with aq.NaOH to give acid <bold>7</bold>.</p><fig id="SCH0001" orientation="portrait" position="float"><label>Scheme 1.</label><caption><p>Synthesis of the compounds <bold>2&#x02013;7</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1690481_SCH0001_B"/></fig><p>A couple of methyl groups at 4-position is most frequently found in the terpenoid scaffold. As shown in <xref ref-type="scheme" rid="SCH0002">Scheme 2</xref>, the conversion of the COOH at 4-position to CH<sub>3</sub> was also investigated. Acids <bold>1</bold> and <bold>2</bold> were firstly esterified by treatment with EtI and K<sub>2</sub>CO<sub>3</sub> to give corresponding esters, which were subsequently reduced to afford alcohols. Conversion of alcohols to its tosylates in pyridine proceeded in satisfactory yield. Zn/NaI reduction<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref> of abietane-tosylates afforded dienes <bold>11&#x02013;12</bold> in satisfactory yield, respectively. Then, diene <bold>12</bold> was oxidative rearranged with SeO<sub>2</sub> to obtain alcohol <bold>13</bold>, which was converted to phenol <bold>14</bold> by hydroperoxide rearrangement.</p><fig id="SCH0002" orientation="portrait" position="float"><label>Scheme 2.</label><caption><p>Synthesis of the compounds <bold>8&#x02013;14</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1690481_SCH0002_B"/></fig><p>The final products <bold>15&#x02013;34</bold> were synthesised via nucleophilic substitution of <bold>6&#x02009;b</bold> and corresponding tosylate or alkyl bromide, and subsequent deprotection of O-protected intermediates (<xref ref-type="scheme" rid="SCH0003">Scheme 3(A&#x02013;C)</xref>). As shown in <xref ref-type="scheme" rid="SCH0003">Scheme 3(A)</xref>, the tosylate intermediates of <bold>15&#x02013;19</bold> and <bold>25&#x02013;34</bold> were provided from corresponding alcohols, which were synthesised via condensation of the acids with different rings and diols with different length in the presence of DCC/DMAP. As shown in <xref ref-type="scheme" rid="SCH0003">Scheme 3(B)</xref>, the tosylate intermediates of <bold>20&#x02013;23</bold> were provided from corresponding alcohols, which were synthesised via nucleophilic substitution. As shown in <xref ref-type="scheme" rid="SCH0003">Scheme 3(C)</xref>, the alkyl bromide intermediate of <bold>24</bold> was synthesised from the phenol and bromoacetyl bromide in alkaline condition.</p><fig id="SCH0003" orientation="portrait" position="float"><label>Scheme 3.</label><caption><p>Synthesis of the compounds <bold>15&#x02013;34</bold>.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1690481_SCH0003_B"/></fig></sec><sec id="s0004"><label>2.2.</label><title>Enzymatic hPTP1B inhibitory activities and SAR analysis</title><p>As shown in <xref rid="t0001" ref-type="table">Table 1</xref>, the PTP1B inhibitory activities of abietic derivatives with two types of terpenoid scaffolds (A and B) were firstly evaluated. Structure&#x02013;activity relationship (SAR) was also discussed. The carboxyl group at 4-position was beneficial for PTP1B inhibition. Esterification of the carboxyl group to give corresponding ethyl ester (<bold>3</bold> vs <bold>4a</bold>), or reduction to the corresponding alcohol (<bold>1</bold> vs <bold>9</bold>, <bold>3</bold> vs <bold>5</bold>) all resulted in loss of activity. Replacing the carboxyl group at 4-position with methyl group resulted in significant drop in activity (<bold>1</bold> vs <bold>11</bold>). Besides, transformation of hydroxy isopropyl group at 13-position of 8,11,13-podocarpatriene derivatives (scaffold B) to hydroxy group (<bold>3</bold> vs <bold>7</bold>, <bold>13</bold> vs <bold>14</bold>) resulted in loss of activity.</p><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>The PTP1B inhibitory activities of abietic derivatives <bold>1&#x02013;14.</bold></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th colspan="5" align="left"><inline-graphic xlink:href="IENZ_A_1690481_ILG0001.gif"/><hr/></th></tr><tr><th align="left">Cpd.</th><th align="center">terpenoid scaffold</th><th align="center">X</th><th align="center">Y</th><th align="center">Inh%@10 &#x003bc;M<sup>a</sup></th></tr></thead><tbody valign="top"><tr><td align="left"><bold>1</bold></td><td align="center">A</td><td align="left">COOH</td><td align="left">C(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">35</td></tr><tr><td align="left"><bold>3</bold></td><td align="center">B</td><td align="left">COOH</td><td align="left">C(CH<sub>3</sub>)<sub>2</sub>OH</td><td align="char" char=".">19</td></tr><tr><td align="left"><bold>4a</bold></td><td align="center">B</td><td align="left">COOEt</td><td align="left">C(CH<sub>3</sub>)<sub>2</sub>OH</td><td align="char" char=".">4</td></tr><tr><td align="left"><bold>5</bold></td><td align="center">B</td><td align="left">CH<sub>2</sub>OH</td><td align="left">C(CH<sub>3</sub>)<sub>2</sub>OH</td><td align="char" char=".">0</td></tr><tr><td align="left"><bold>7</bold></td><td align="center">B</td><td align="left">COOH</td><td align="left">OH</td><td align="char" char=".">1</td></tr><tr><td align="left"><bold>9</bold></td><td align="center">A</td><td align="left">CH<sub>2</sub>OH</td><td align="left">C(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">3</td></tr><tr><td align="left"><bold>10</bold></td><td align="center">A</td><td align="left">CH<sub>2</sub>OTs</td><td align="left">C(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">2</td></tr><tr><td align="left"><bold>11</bold></td><td align="center">A</td><td align="left">CH<sub>3</sub></td><td align="left">C(CH<sub>3</sub>)<sub>2</sub></td><td align="char" char=".">0</td></tr><tr><td align="left"><bold>13</bold></td><td align="center">B</td><td align="left">CH<sub>3</sub></td><td align="left">C(CH<sub>3</sub>)<sub>2</sub>OH</td><td align="char" char=".">22</td></tr><tr><td align="left"><bold>14</bold></td><td align="center">B</td><td align="left">CH<sub>3</sub></td><td align="left">OH</td><td align="char" char=".">15</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><label>a</label><p>These experiments were performed in triplicate.</p></fn></table-wrap-foot></table-wrap><p>Among tricyclic derivatives <bold>15</bold>&#x02013;<bold>34</bold>, the compounds <bold>15</bold> (2.9&#x02009;&#x003bc;M), <bold>28</bold> (4.8&#x02009;&#x003bc;M) and <bold>34</bold> (8.2&#x02009;&#x003bc;M) exhibited the most PTP1B enzymatic inhibitory activities, which were equal to that of the lead compound <bold>C10a</bold> (3.1&#x02009;&#x003bc;M), and they have smaller molecular weight (<xref rid="t0002" ref-type="table">Table 2</xref>). SAR analysis demonstrated that the derivatives with different linker between terpenoid scaffold and ring moiety displayed different PTP1B inhibition activity. The inhibitory activity of PTP1B decreased along with an increase of the length of linker (<bold>15&#x02009;&#x0003e;&#x02009;16&#x02009;&#x0003e;&#x02009;17</bold>). Also, the structure of the linker influenced PTP1B inhibition. Compared with <bold>20</bold> and <bold>24</bold>, <bold>15</bold> displayed higher PTP1B inhibitory activity. Besides, the derivatives containing a benzene or naphthalene at the ring moiety (<bold>15</bold>, <bold>18&#x02013;19</bold>, <bold>25&#x02013;28</bold> and <bold>34</bold>) showed higher inhibitory activity relative to the analogues bearing the heteroaromatic ring (<bold>29</bold>) or alicyclic ring (<bold>31&#x02013;33</bold>). At the ring moiety, a clear preference was identified for the polar groups, with an increase in activity for the carboxyl group (<bold>15</bold> and <bold>34</bold>) and amino group (<bold>28</bold>), whereas substitution with carboxylmethyl group (<bold>30</bold>) led to significant loss of activity. The benzene ring with a carboxyl group at the <italic>o</italic>-position (<bold>15</bold>) increased the potency relative to those at the <italic>p</italic>-position (<bold>18</bold>) or <italic>m</italic>-position (<bold>19</bold>). Overall, our data demonstrated these compounds with tricyclic diterpene moiety are potent PTP1B inhibitors.</p><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>The PTP1B inhibitory activities of tricyclic derivatives <bold>15&#x02013;34.</bold></p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><tbody valign="top"><tr><td align="left"><inline-graphic xlink:href="IENZ_A_1690481_ILG0002.gif"/></td><td style="">&#x000a0;</td><td style="">&#x000a0;</td><td style="">&#x000a0;</td><td style="">&#x000a0;</td><td style="">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><label>a</label><p>These experiments were performed in triplicate.</p></fn><fn id="TF3"><label>b</label><p>SD: standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s0005"><label>2.3.</label><title>Cellular glucose uptake in insulin-resistant HepG2 cells</title><p>To assess the insulin sensitisation, the cellular effect of these compounds on insulin-resistant human hepatoma HepG2 cells was performed. The concentration of insulin and induction time were screened to induce insulin resistance in HepG2 cells according to the reported method<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref><sup>,</sup><xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref> with some modification. As shown in <xref ref-type="fig" rid="F0004">Figure 4(A)</xref>, treatment with above 1&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5&#x02009;</sup>mmol of insulin reduced glucose uptake, whereas treatment with 6&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6&#x02009;</sup>mmol of insulin enhanced glucose uptake. Insulin resistance can be obviously observed when the HepG2 cells were treatment with 1.5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5&#x02009;</sup>mmol of insulin, and an insulin sensitiser (rosiglitazone) can significantly decrease the insulin resistance and improve the glucose uptake. Treatment with higher concentration (&#x0003e;2&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5&#x02009;</sup>mmol) of insulin inhibited cell growth, and microscopic examination revealed atrophy of the cells. As shown in <xref ref-type="fig" rid="F0004">Figure 4(B)</xref>, insulin resistance was induced in HepG2 cells at 36&#x02009;h, and rosiglitazone can decrease the insulin resistance. The cell growth was accelerated after 36&#x02009;h and insulin resistance was decreased along with induction time. Therefore, the cells were treated with 1.5&#x02009;&#x000d7;&#x02009;1 0 <sup>&#x02212;5&#x02009;</sup>mmol of insulin for 36&#x02009;h to induce the insulin resistance and produce the most obvious difference of glucose consumption between insulin resistance group (M group) and rosiglitazone group (Y group).</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>The effect of the compounds on glucose consumption in insulin-resistant HepG2 cells. (A) The HepG2 cells were induced with different concentrations of insulin; (B) The HepG2 cells were induced for different induction times; (C) HepG2 cells were induced with 1.5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5&#x02009;</sup>mmol of insulin for 36&#x02009;h to afford insulin-resistant cells, and then treated with rosiglitazone (Y group) or the compounds for 24&#x02009;h. After incubation, glucose content in the culture medium was measured by glucose oxidase method. M group: insulin-resistant HepG2 cells without rosiglitazone and the compounds; K group: HepG2 cells without induction by insulin.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1690481_F0004_B"/></fig><p>As shown in <xref ref-type="fig" rid="F0004">Figure 4(C)</xref>, most compounds can enhance the glucose consumption in insulin-resistant HepG2 cells, and the insulin stimulatory effects on glucose uptake were similar to that of <bold>C10a</bold>, but inferior to that of rosiglitazone. Cell viability was evaluated with the MTT assay and the result demonstrated that the cytotoxicities of most compounds were acceptable, while <bold>C10a</bold> showed the considerable cytotoxicity (see <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14756366.2019.1690481">Figure 1S, Supplementary material</ext-link>). Compared with <bold>15</bold>, which exhibited the most PTP1B enzymatic inhibitory potency, compound <bold>25</bold> has lower PTP1B inhibition (26.2&#x02009;&#x003bc;M), but it can more significantly increase insulin-stimulated glucose uptake in cellular assay. This result was unsurprising, because most active site-directed PTP1B inhibitors are phosphotyrosine mimetics with weak cell permeability<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>. We have previously reported that there is a trade-off between enzymatic inhibition and cell permeability<xref rid="CIT0018" ref-type="bibr"><sup>18</sup></xref>. We calculated the pharmaceutical properties of <bold>15</bold>, <bold>25</bold> and <bold>C10a</bold> using the Swiss ADME. As shown in <xref rid="t0003" ref-type="table">Table 3</xref>, the MW and cLog<italic>P</italic> value of <bold>C10a</bold> are too large, as well as the HB acceptors of <bold>15</bold>. Both of these compounds could not fulfil Lipinski Rule<xref rid="CIT0044" ref-type="bibr"><sup>44</sup></xref>. <bold>25</bold> fulfilled Lipinski Rule of Five and has the lowest TPSA, which means more acceptable oral absorption and cell permeability. These results demonstrated <italic>in silico</italic> preferable pharmaceutical properties of <bold>25</bold> were beneficial for its cellular effect.</p><table-wrap id="t0003" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Pharmaceutical properties of <bold>15</bold>, <bold>25</bold> and <bold>C10a</bold>.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Cpd.</th><th align="center">MW</th><th align="center">HB donors</th><th align="center">HB acceptors</th><th align="center">cLog <italic>P</italic></th><th align="center">Rotatable bonds</th><th align="center">TPSA<break/>(&#x000c5;<sup>2</sup>)</th><th align="center">GI absorption</th><th align="center">P-gp substrate</th><th align="center">Cytotoxicity</th></tr></thead><tbody valign="top"><tr><td align="left"><bold>15</bold></td><td align="left">466</td><td align="left">2</td><td align="left">7</td><td align="char" char=".">4.23</td><td align="char" char=".">8</td><td align="char" char=".">110.13</td><td align="left">High</td><td align="left">Yes</td><td align="left">Low</td></tr><tr><td align="left"><bold>25</bold></td><td align="left">422</td><td align="left">1</td><td align="left">5</td><td align="char" char=".">4.68</td><td align="char" char=".">7</td><td align="char" char=".">72.83</td><td align="left">High</td><td align="left">Yes</td><td align="left">Low</td></tr><tr><td align="left"><bold>C10a</bold></td><td align="left">588</td><td align="left">1</td><td align="left">5</td><td align="char" char=".">7.32</td><td align="char" char=".">5</td><td align="char" char=".">80.67</td><td align="left">Low</td><td align="left">No</td><td align="left">High</td></tr></tbody></table><table-wrap-foot><fn id="TF4"><p>cLog <italic>P</italic>: consensus log of the octanol/water partition coefficient; GI absorption: gastrointestinal absorption; MW: molecular weight; TPSA: topological polar surface area.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s0006"><label>2.4.</label><title>The antihyperglycaemic effect in NIDDM mice</title><p>The antihyperglycaemic effect of the compounds <bold>15</bold>, <bold>25</bold> and <bold>C10a</bold> were evaluated on non-insulin dependent diabetes mellitus (NIDDM) mice. Nicotinamide and streptozotocin were administrated intraperitoneally to induce hyperglycaemia and the plasma glucose of mice raised over 4.5&#x02009;mmol/L<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref>. Rosiglitazone has not shown effect during the first hour, but it showed the significant antihyperglycaemic effect after 1&#x02009;h (<xref ref-type="fig" rid="F0005">Figure 5(A,B)</xref>). Though <bold>C10a</bold> showed the antihyperglycaemic effect, some mice treated with <bold>C10a</bold> appeared the hydroabdomen, thrombus and tail necrosis, suggesting the acute toxicity of <bold>C10a</bold>. Compared with <bold>15</bold>, <bold>25</bold> showed <italic>in&#x000a0;vivo</italic> antihyperglycaemic effect, correlating with insulin-resistant cell assay.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>The antihyperglycaemic effect in NIDDM mice (<italic>n</italic>&#x02009;=&#x02009;8). (A) Diminution of plasmatic glucose concentration over NIDDM mice treated with <bold>15</bold>, <bold>25</bold>, <bold>C10a</bold> and rosiglitazone, respectively; (B) The acute antidiabetic effect of <bold>25</bold> were observed with respect to positive control. M group: NIDDM mice were treated with saline alone. Y group: NIDDM mice were treated with rosiglitazone.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1690481_F0005_B"/></fig></sec></sec><sec id="s0007"><label>3.</label><title>Conclusions</title><p>In this article, a series of tricyclic derivatives containing various hydrophobic scaffold, linker and aryl moiety were designed and synthesised from 13-hydroxy-8,11,13-podocarpatriene, and their inhibitory activity against the PTP1B enzyme was assessed. Among these compounds, some tricyclic derivatives were described as potent inhibitors of PTP1B. Compound <bold>25</bold> showed the most effect on glucose consumption in insulin-resistant HepG2 cells. Moreover, <bold>25</bold> showed the most antihyperglycemic effect in NIDDM mice. The therapeutic potential of PTP1B inhibition, as well as the insulin sensitising and <italic>in&#x000a0;vivo</italic> antihyperglycemic effect of these compounds, made this discovery an important opportunity.</p></sec><sec id="s0008"><label>4.</label><title>Experimental section</title><sec id="s0009"><label>4.1.</label><title>Chemistry</title><p><sup>1</sup>H NMR spectra were recorded on a Bruker Avance 400 spectrometer. <sup>13</sup>C NMR spectra were recorded on a Bruker DPX 300 spectrometer. TMS was the internal standard. Chemical shifts as &#x003b4; values were recorded in ppm and coupling constants as J values were recorded in Hz. HRMS spectra were recorded on a micrOTOF-Q II 10203 spectrometer. TLC were performed on the HSGF254 silica gel and UV detection at 254&#x02009;nm and 365&#x02009;nm, and appropriate chromogenic agents.</p><sec id="s0010"><label>4.1.1.</label><title>Synthesis of abieta-8(9),13(15)-dien-18-oic acid (2)</title><p>To a solution of <bold>1</bold> (20.00&#x02009;g, 66.40&#x02009;mmol) in 64&#x02009;ml of HOAc was added to 33% HBr/HOAc (64&#x02009;ml). The mixture was stirred at rt for 6&#x02009;h, and then was filtered and the filter cake was washed with HOAc, dried in vacuum overnight to give corresponding crude dibromo derivative. To a solution of the crude 8,15-dibromo derivative was added LiOH (2.64&#x02009;g, 64.72&#x02009;mmol) in 200&#x02009;ml of DMF, and the mixture was stirred at 80&#x02009;&#x000b0;C for 7&#x02009;h. Solvent was removed under reduced pressure, and the pH was adjusted to 3 with HCl (aq) and concentrated to give a brown oil <bold>2</bold> without further purification.</p></sec><sec id="s0011"><label>4.1.2.</label><title>General procedure 1: SeO<sub>2</sub>-mediated oxidative rearrangement</title><p>To a solution of 1 equiv. diene in 10&#x02009;ml/mmol of dry THF was added 4 equiv. SeO<sub>2</sub>, and the mixture was stirred at 0&#x02009;&#x000b0;C for 5&#x02009;h under an atmosphere of Ar. The solid was removed by filtration, and the filtrate was extracted with EtOAc. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to give product.</p><p><italic>15-Hydroxydehydroabieta-18-oic acid (</italic><bold><italic>3</italic></bold><italic>).</italic> Yellow oil; mp: 92&#x02013;93&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.24 (m, 2H), 7.18 (s, 1H), 2.96 (m, 1H), 2.43&#x02013;2.00 (m, 3H), 1.92&#x02013;1.85 (m, 2H), 1.85&#x02013;1.77 (m, 2H),1.77&#x02013;1.70 (s, 3H), 1.58 (s, 6H), 1.46 (s, 3H), 1.31 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>): &#x003b4; 184.5, 147.8, 145.9, 134.7, 124.9, 124.1, 121.9, 120.2, 72.4, 60.4, 47.3, 44.5, 37.8, 36.9, 36.7, 31.6, 30.1, 25.0, 18.5, 16.2. HRMS (AP-ESI) Calcd. For C<sub>20</sub>H<sub>28</sub>NaO<sub>3</sub>: 339.2038 [M&#x02009;+&#x02009;Na]<sup>+</sup>. Found: 339.2087.</p><p><italic>15-Hydroxydehydroabietane (</italic><bold><italic>13</italic></bold><italic>).</italic> Yellow oil; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.80 (d, <italic>J</italic>&#x02009;=&#x02009;8.2&#x02009;Hz, 1H), 7.37 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x02009;Hz, 1H), 7.22 (s, 1H), 5.32 (s, 1H), 3.85 (d, <italic>J</italic>&#x02009;=&#x02009;9.3&#x02009;Hz, 1H), 3.62 (d, <italic>J</italic>&#x02009;=&#x02009;9.4&#x02009;Hz, 1H), 2.93&#x02013;2.73 (m, 2H), 2.48 (s, 3H), 1.71 (m, 2H), 1.60 (s, 3H), 1.58 (s, 3H), 1.51&#x02013;1.30 (m, 6H), 1.20 (s, 3H), 0.91 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 129.8, 127.9, 124.8, 124.2, 121.9, 77.6, 72.2, 43.5, 38.0, 37.3, 37.1, 35.0, 31.6, 29.9, 21.6, 18.8, 18.3, 17.1. HRMS (AP-ESI) Calcd. for C<sub>20</sub>H<sub>30</sub>NaO: 309.2195 [M&#x02009;+&#x02009;Na]<sup>+</sup>. Found: 309.2185.</p></sec><sec id="s0012"><label>4.1.3.</label><title>General procedure 2: K<sub>2</sub>CO<sub>3</sub>-mediated esterification</title><p>To a solution of 1 equiv. abieta-18-oic acid in acetone was added 3 equiv. K<sub>2</sub>CO<sub>3</sub>, and the mixture was stirred for 15&#x02009;min. The solution was dropwise added 2 equiv. EtI (for <bold>4a</bold> and <bold>8</bold>) or BnBr (for <bold>4&#x02009;b</bold>) and the mixture was stirred at 60&#x02009;&#x000b0;C for 3&#x02009;h. The mixture was extracted with EtOAc. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to give product.</p><p><italic>Ethyl 15-hydroxydehydroabietate (</italic><bold><italic>4a</italic></bold><italic>).</italic> Yellow solid; mp: 51&#x02013;52&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.26 (s, 2H), 7.19 (s, 1H), 4.11&#x02013;4.18 (m, 2H), 3.05&#x02013;2.61 (m, 2H), 2.44&#x02013;2.25 (m, 2H), 1.91&#x02013;1.83 (m, 2H), 1.83&#x02013;1.70 (m, 3H),1.31&#x02013;1.27 (m, 5H), 1.26 (s, 3H), 1.24 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 178.4, 147.8, 145.9, 134.6, 126.8, 124.8, 124.1, 121.9, 72.1, 60.4, 47.3, 44.6, 37.8, 36.9, 36.4, 31.5, 30.2, 29.6, 25.0, 23.9, 21.5, 18.5, 16.4, 14.1. HRMS (AP-ESI) Calcd. for C<sub>22</sub>H<sub>32</sub>KO<sub>3</sub>: 283.1988 [M&#x02009;+&#x02009;K]<sup>+</sup>. Found: 383.1933.</p><p><italic>Benzyl 15-hydroxydehydroabietate (</italic><bold><italic>4&#x02009;b</italic></bold><italic>).</italic> Yellow solid; mp: 112&#x02013;113&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.42&#x02013;7.31 (m, 1H), 7.26&#x02013;7.15 (m, 1H), 7.06&#x02013;7.00 (m, 1H), 6.89 (s, 1H), 5.19 (dd, <italic>J</italic>&#x02009;=&#x02009;12.4, 3.4&#x02009;Hz, 2H), 5.10 (s, 1H), 5.07 (s, 1H), 2.91&#x02013;2.75 (m, 1H), 2.36&#x02013;2.25 (m, 1H), 1.86&#x02013;1.61 (m, 2H), 1.33&#x02013;1.31 (m, 1H), 1.29 (s, 1H), 1.24 (dd, <italic>J</italic>&#x02009;=&#x02009;6.4, 3.8&#x02009;Hz, 1H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 177.9, 146.9, 145.7, 136.1, 134.7, 128.9, 127.6, 127.1, 124.9, 124.3, 123.0, 73.9, 67.0, 51.8, 43.8, 38.4, 37.6, 31.6, 30.0, 28.3, 24.7, 20.1, 19.7. HRMS (AP-ESI) Calcd. for C<sub>27</sub>H<sub>35</sub>O<sub>3</sub>: 407.2581 [M&#x02009;+&#x02009;H]<sup>+</sup>. Found: 407.2585.</p></sec><sec id="s0013"><label>4.1.4.</label><title>General procedure 3: LiAlH<sub>4</sub>- participated reduction</title><p>To a suspension of 4 equiv. LiAlH<sub>4</sub> in THF was added 1 equiv. ester in 10&#x02009;ml/mmol of THF at 0&#x02009;&#x000b0;C. The mixture was stirred at rt for 3&#x02009;h, and then was quenched by addition of aq.NaOH. The resulting solid was filtered off. Solvent of the filtrate was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to give product.</p><p><italic>1-Hydroxylmethyl-15-hydroxydehydroabietate (</italic><bold><italic>5</italic></bold><italic>)</italic>. Colourless oil; <sup>1</sup>H NMR (400&#x02009;MHz, <italic>d<sub>6</sub></italic>-DMSO) &#x003b4; 12.17 (br, 1H), 8.99 (br, 1H), 7.03 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 1H), 6.53 (dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 2.5&#x02009;Hz, 1H), 6.37 (d, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, 1H), 4.12 (br, 1H), 3.17 (d, <italic>J</italic>&#x02009;=&#x02009;2.0&#x02009;Hz, 2H), 2.73&#x02013;2.67 (m, 2H), 2.25 (d, <italic>J</italic>&#x02009;=&#x02009;12.4&#x02009;Hz, 1H), 2.00 (dd, <italic>J</italic>&#x02009;=&#x02009;12.3, 1.6&#x02009;Hz, 1H), 1.75&#x02013;1.55 (m, 8H), 1.38&#x02013;1.24 (m, 4H), 1.15 (s, 3H), 1.09 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, <italic>d<sub>6</sub></italic>-DMSO) &#x003b4; 179.9, 155.0, 140.5, 135.8, 125.5, 114.9, 113.6, 53.7, 49.0, 46.7, 45.3, 38.4, 36.7, 36.5, 30.0, 25.4, 21.6, 18.6, 16.7, 14.4. HRMS (AP-ESI) Calcd. for C<sub>20</sub>H<sub>31</sub>O<sub>2</sub>: 303.2246 [M&#x02009;+&#x02009;Na]<sup>+</sup>. Found: 303.2221.</p><p><italic>1-Hydroxymethylabietane (</italic><bold><italic>9</italic></bold><italic>).</italic> Yellow solid; mp: 125&#x02013;126&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 5.81 (s, 1H), 5.49&#x02013;5.42 (m, 1H), 4.25 (s, 1H), 3.54&#x02013;3.45 (m, 2H), 2.37&#x02013;1.92 (m, 6H), 1.91&#x02013;1.77 (m, 4H), 1.67&#x02013;1.52 (m, 5H), 1.53&#x02013;1.40 (m, 4H), 1.34&#x02013;1.26 (m, 6H), 1.26&#x02013;1.20 (s, 3H), 1.20&#x02013;1.15 (m, 6H), 1.09&#x02013;0.98 (m, 8H), 0.98&#x02013;0.86 (m, 11H), 0.81 (s, 4H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 146.0, 145.9, 134.7, 124.9, 124.1, 121.9, 75.7, 72.4, 48.3, 44.5, 37.8, 36.9, 36.7, 31.6, 30.2, 25.0, 21.7, 19.5, 14.2. HRMS (AP-ESI) Calcd. for C<sub>20</sub>H<sub>33</sub>O: 289.2526 [M&#x02009;+&#x02009;Na]<sup>+</sup>. Found: 289.2531.</p></sec><sec id="s0014"><label>4.1.5.</label><title>General procedure 4: t-BuOOH-mediated hydroperoxide rearrangement</title><p>To a solution of 1 equiv. ester <bold>5</bold> in 5&#x02009;ml/mmol AcOH was added 3 equiv. <italic>t</italic>-BuOOH followed by addition of 0.1 equiv. H<sub>2</sub>SO<sub>4</sub>. The mixture was stirred at 50&#x02009;&#x000b0;C for 1&#x02009;h. The mixture was diluted with water and the aqueous phase was extracted with DCM. The organic phase was washed with Na<sub>2</sub>CO<sub>3</sub> (aq), water and dried. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to furnish the product.</p><p><italic>Ethyl 13-hydroxy-8,11,13-podocarpatriene-1-carboxylate (</italic><bold><italic>6a</italic></bold><italic>).</italic> White solid; mp: 96&#x02013;97&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.12 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 1H), 6.66 (dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 2.6&#x02009;Hz, 1H), 6.53 (d, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, 1H), 5.25 (br, 1H), 4.35&#x02013;3.96 (m, 2H), 2.85 (dd, <italic>J</italic>&#x02009;=&#x02009;10.8, 5.2&#x02009;Hz, 2H), 2.44&#x02013;2.17 (m, 2H), 1.90&#x02013;1.62 (m, 7H), 1.29&#x02013;1.24 (m, 6H), 1.21 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 178.8, 153.2, 142.0, 136.6, 125.5, 114.8, 113.1, 60.6, 47.4, 44.9, 38.1, 36.5, 30.1, 25.2, 23.6, 21.5, 18.6, 16.4, 14.2. ESI-MS: 303.1 [M&#x02009;+&#x02009;H]<sup>+</sup>.</p><p><italic>Benzyl 13-hydroxy-8,11,13-podocarpatriene-1-carboxylate (</italic><bold><italic>6&#x02009;b</italic></bold><italic>).</italic> White solid; mp: 102&#x02013;103&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 9.26 (s, H),7.44&#x02013;7.31 (m, 6H), 7.27&#x02013;7.16 (m, 2H), 2.88&#x02013;2.78 (m, 2H), 2.35&#x02013;2.20 (m, 2H), 1.85 &#x02013;1.67 (m, 2H), 1.58 (s, 3H), 1.23 (d, <italic>J</italic>&#x02009;=&#x02009;3.3&#x02009;Hz, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 178.5, 153.1, 142.0, 136.6, 136.3, 128.5, 128.1, 128.1, 125.6, 114.9, 113.1, 66.4, 47.7, 45.0, 38.1, 36.4, 36.5, 30.0, 25.3, 21.5, 18.6, 16.6. HRMS (AP-ESI) Calcd. for C<sub>24</sub>H<sub>29</sub>O<sub>3</sub>: 365.2111 [M&#x02009;+&#x02009;H]<sup>+</sup>. Found: 365.2119.</p><p><italic>13-Hydroxy-8,11,13-podocarpatriene (</italic><bold><italic>14</italic></bold><italic>).</italic> Yellow solid. mp: 145&#x02013;146&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.14 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 1H), 6.64 (dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 2.7&#x02009;Hz, 1H), 6.53 (d, <italic>J</italic>&#x02009;=&#x02009;2.6&#x02009;Hz, 1H), 4.77 (s, 1H), 3.02&#x02013;2.65 (m, 2H), 1.88 (m, 1H)1.81&#x02013;1.56 (m, 4H), 1.54&#x02013;1.33 (m, 2H), 1.33&#x02013;1.23 (m, 2H),1.19 (s, 3H), 0.97 (s, 3H), 0.95 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 148.1, 138.1, 132.2, 120.9, 110.1, 108.2, 45.8, 37.0, 34.3, 32.6, 28.7, 28.6, 25.7, 20.2, 16.9, 14.6, 14.3. HRMS (AP-ESI) Calcd. for C<sub>17</sub>H<sub>25</sub>O: 245.1878 [M&#x02009;+&#x02009;H]<sup>+</sup>. Found: 245.1895.</p></sec><sec id="s0015"><label>4.1.6.</label><title>Synthesis of 13-hydroxy-8,11,13-podocarpatriene-1-carboxylic acid (7)</title><p>To a solution of <bold>6</bold> (0.10&#x02009;g, 0.33&#x02009;mmol) in 4&#x02009;ml EtOH/H<sub>2</sub>O (1:1) was added NaOH (13.1&#x02009;mg, 0.99&#x02009;mmol), and the mixture was stirred at 100&#x02009;&#x000b0;C for 2&#x02009;h. The mixture was cooled to rt and pH was adjusted to 6 with HCl(aq). The resulting solid was filtered off to give the product <bold>7</bold> (82.5&#x02009;mg, 91%) as a white solid. mp: 101&#x02013;102&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, <italic>d</italic><sub>6</sub>-DMSO) &#x003b4; 12.17 (br, 1H), 8.99 (br, 1H), 7.03 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 1H), 6.51 (dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 2.5&#x02009;Hz, 1H), 6.38 (d, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, 1H), 2.82&#x02013;2.60 (m, 1H), 2.25 (d, <italic>J</italic>&#x02009;=&#x02009;12.4&#x02009;Hz, 1H), 2.00 (dd, <italic>J</italic>&#x02009;=&#x02009;12.3, 1.6&#x02009;Hz, 1H), 1.78&#x02013;1.67 (m, 2H), 1.67&#x02013;1.56 (m, 2H), 1.56&#x02013;1.45 (m, 2H), 1.44&#x02013;1.18 (m, 2H), 1.16 (s, 3H), 1.10 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, <italic>d</italic><sub>6</sub>-DMSO) &#x003b4; 180.0, 155.1, 140.5, 135.9, 125.5, 115.0, 113.6, 46.8, 45.4, 40.6, 39.3, 36.5, 30.1, 25.5, 21.6, 18.7, 16.8. HRMS (AP-ESI) Calcd. for C<sub>17</sub>H<sub>22</sub>NaO<sub>3</sub>: 297.1467 [M&#x02009;+&#x02009;Na]<sup>+</sup>. Found: 297.1461.</p></sec><sec id="s0016"><label>4.1.7.</label><title>General procedure 5: TsCl-participated sulfonylation</title><p>The solution of 1 equiv. alcohol and 5 equiv. tolylsulfonyl chloride in 3&#x02009;ml/mmol of pyridine was stirred at rt for 6&#x02009;h. After removal of solvent by evaporation, the mixture was dissolved in DCM, followed by washed and dried. The mixture was then concentrated and subjected to flash column chromatography to furnish the product.</p><p><italic>1-Hydroxymethyl-abietane-p-methylbenzenesulfonate (</italic><bold><italic>10</italic></bold><italic>)</italic>. White solid; mp:67&#x02013;68&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.74&#x02013;7.66 (d, 2H), 7.40&#x02013;7.51 (d, 2H),5.81 (s, 1H), 5.58&#x02013;5.34 (m, 1H), 2.53 (s, 3H),2.32&#x02013;1.94 (m, 4H), 1.93&#x02013;1.77 (m, 2H), 1.67&#x02013;1.54 (m, 3H), 1.50&#x02013;1.42 (m, 1H), 1.34&#x02013;1.16 (m, 6H), 1.03 (dd, <italic>J</italic>&#x02009;=&#x02009;6.8, 4.0&#x02009;Hz, 6H), 0.94 (q, <italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, 3H), 0.92&#x02013;0.84 (m, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 146.0, 144.4, 140.4, 133.5, 130.5, 128.3, 122.4, 121.3, 73.1, 51.7, 51.1, 39.5, 37.0, 35.4, 34.9, 27.7, 24.2, 22.7, 21.0, 20.3, 18.4, 14.7. HRMS (AP-ESI) Calcd. for C<sub>27</sub>H<sub>39</sub>O<sub>3</sub>S: 443.2614 [M&#x02009;+&#x02009;H]<sup>+</sup>. Found: 443.2619.</p></sec><sec id="s0017"><label>4.1.8.</label><title>General procedure 6: Zn/NaI-mediated reduction</title><p>The solution of 1 equiv. <italic>p</italic>-toluenesulfonate, 10 equiv. zinc and 5 equiv. sodium iodide in 10&#x02009;ml/mmol of HMPA was stirred at 105&#x02009;&#x000b0;C for 7&#x02009;h. The mixture was dissolved in water and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine and dried. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to furnish the product.</p><p><italic>7-Isopropyl-1,1,4-trimethyl-decahydrophenanthrene (</italic><bold><italic>11</italic></bold><italic>)</italic>. White oil<italic>;</italic><sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 5.81 (s, 1H), 5.58&#x02013;5.34 (m, 1H), 2.32&#x02013;1.94 (m, 2H), 1.93&#x02013;1.77 (m, 2H), 1.67&#x02013;1.54 (m, 3H), 1.50&#x02013;1.42 (m, 1H), 1.34&#x02013;1.16 (m, 6H), 1.03 (dd, <italic>J</italic>&#x02009;=&#x02009;6.8, 4.0&#x02009;Hz, 6H), 0.94 (q, <italic>J</italic>&#x02009;=&#x02009;6.5&#x02009;Hz, 3H), 0.92&#x02013;0.84 (m, 3H), 0.81 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, <italic>d<sub>6</sub></italic>-DMSO) &#x003b4; 142.6, 137.5, 123.5, 120.6, 52.2, 50.4, 41.8, 40.4, 39.6, 35.05, 33.5, 31.6, 22.7, 20.8, 19.1, 18.4, 15.2, 14.3. HRMS (AP-ESI) Calcd. for C<sub>20</sub>H<sub>31</sub>: 271.2426 [M &#x02013; H]<sup>&#x02212;</sup>. Found: 271.2242.</p></sec><sec id="s0018"><label>4.1.9.</label><title>General procedure 7: DCC-promoted condensation</title><p>To a solution of 1 equiv. carboxylic acid in 1.5 equiv. diol was added to a solution of 1.5 equiv. DCC and 0.05 equiv. DMAP in 5&#x02009;ml/mmol of acetonitrile. The mixture was stirred at 0&#x02009;&#x000b0;C for 1&#x02009;h, then transferred to rt and stirred for 5&#x02009;h. The mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to furnish the product.</p></sec><sec id="s0019"><label>4.1.10.</label><title>General procedure 8: K<sub>2</sub>CO<sub>3</sub>-mediated nucleophilic substitution</title><p>A solution of 3 equiv. ester in 2&#x02009;ml/mmol of DMF was added to a solution of 1 equiv. <bold>6b</bold> and 5 equiv. K<sub>2</sub>CO<sub>3</sub> in 2&#x02009;ml/mmol of DMF. The mixture was stirred at 80&#x02009;&#x000b0;C for 5&#x02009;h. The mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried. Solvent was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to furnish the product.</p></sec><sec id="s0020"><label>4.1.11.</label><title>General procedure 9: Pd/C-catalyzed hydrogenolysis of the O-protected group</title><p>Pd/C (10%, 1&#x02009;mg/mg) was added to the solution of 1 equiv. benzyl ester in 10&#x02009;ml/mmol of methanol. The mixture was hydrogenolised under 1&#x02009;MPa at rt for 12&#x02009;h. The reaction mixture was filtered. Solvent of the filtrate was removed under reduced pressure, and the resulting residue was purified by flash column chromatography to furnish the product.</p><p><italic>Compound</italic>
<bold><italic>15</italic></bold>. White solid; mp: 72&#x02013;73&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.91 (d, <italic>J</italic>&#x02009;=&#x02009;7.0&#x02009;Hz, 1H), 7.67 (d, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, 1H), 7.63&#x02013;7.44 (m, 2H), 7.12 (t, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 1H), 6.73 (dd, <italic>J</italic>&#x02009;=&#x02009;8.5, 1.9&#x02009;Hz, 1H), 6.58 (s, 1H), 4.64 (s, 2H), 4.23 (s, 1H), 4.15 (q, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, 1H), 2.84 (d, <italic>J</italic>&#x02009;=&#x02009;5.4&#x02009;Hz, 2H), 2.35&#x02013;2.11 (m, 2H), 2.08 (s, 1H), 1.92&#x02013;1.65 (m, 6H), 1.29 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, 5H), 1.19 (d, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.4, 179.8, 173.7, 171.3, 156.1, 142.4, 136.3, 130.9, 129.9, 128.8, 125.5, 125.4, 115.0, 114.1, 113.1, 112.9, 65.5, 60.5, 47.4, 44.7, 38.0, 36.6, 30.2, 25.2, 21.7, 18.5, 16.2, 14.2. HRMS (AP-ESI) Calcd. for C<sub>27</sub>H<sub>29</sub>O<sub>7</sub>: 465.1919 [M &#x02013; H]<sup>&#x02212;</sup>. Found: 465.1921.</p><p><italic>Compound</italic>
<bold><italic>16</italic></bold>. White solid; mp: 109&#x02013;110&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.92 (d, <italic>J</italic>&#x02009;=&#x02009;6.8&#x02009;Hz, 1H), 7.70 (d, <italic>J</italic>&#x02009;=&#x02009;7.1&#x02009;Hz, 1H), 7.59 (dt, <italic>J</italic>&#x02009;=&#x02009;13.2, 7.2&#x02009;Hz, 2H), 7.14 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 6.71 (dd, <italic>J</italic>&#x02009;=&#x02009;8.6, 2.8&#x02009;Hz, 1H), 6.56 (dd, <italic>J</italic>&#x02009;=&#x02009;11.1, 2.6&#x02009;Hz, 1H), 5.32 (s, 2H), 4.64 (dd, <italic>J</italic>&#x02009;=&#x02009;5.8, 2.8&#x02009;Hz, 1H), 4.52 (t, <italic>J</italic>&#x02009;=&#x02009;6.3&#x02009;Hz, 1H), 4.29 (d, <italic>J</italic>&#x02009;=&#x02009;5.2&#x02009;Hz, 1H), 4.06 (t, <italic>J</italic>&#x02009;=&#x02009;6.1&#x02009;Hz, 1H), 4.00 (t, <italic>J</italic>&#x02009;=&#x02009;6.2&#x02009;Hz, 1H), 2.86 (s, 3H), 2.25 (dd, <italic>J</italic>&#x02009;=&#x02009;30.0, 10.2&#x02009;Hz, 4H), 2.11&#x02013;2.02 (m, 1H), 1.91&#x02013;1.78 (m, 4H), 1.78&#x02013;1.68 (m, 3H), 1.35&#x02013;1.24 (m, 5H), 1.20 (s, 3H).13C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.6, 172.5, 168.2, 142.0, 136.3, 133.5, 132.3, 130.8, 129.9, 129.9, 128.7, 125.3, 113.9, 112.7, 64.2, 63.0, 47.5, 44.7, 38.0, 36.7, 36.6, 30.2, 28.4, 25.2, 21.7, 18.5, 16.2. HRMS (AP-ESI) Calcd. for C<sub>28</sub>H<sub>31</sub>O<sub>7</sub>: 479.2075 [M &#x02013; H]<sup>&#x02212;</sup>. Found: 479.2070.</p><p><italic>Compound</italic>
<bold><italic>17</italic></bold>. White solid; mp: 113&#x02013;114&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.69 (d, <italic>J</italic>&#x02009;=&#x02009;6.2&#x02009;Hz, 1H), 7.57 (d, <italic>J</italic>&#x02009;=&#x02009;4.8&#x02009;Hz, 2H), 7.12 (t, <italic>J</italic>&#x02009;=&#x02009;9.5&#x02009;Hz, 2H), 6.67 (dd, <italic>J</italic>&#x02009;=&#x02009;21.8, 7.4&#x02009;Hz, 2H), 6.52 (d, <italic>J</italic>&#x02009;=&#x02009;19.8&#x02009;Hz, 2H), 4.40 (s, 1H), 3.95 (s, 1H), 2.84 (s, 3H), 2.25 (dd, <italic>J</italic>&#x02009;=&#x02009;26.4, 12.1&#x02009;Hz, 4H), 1.97&#x02013;1.67 (m, 12H), 1.29 (s, 6H), 1.20 (s, 6H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 156.4, 141.9, 136.6, 136.3, 131.9, 130.9, 128.7, 125.5, 125.3, 115.0, 113.9, 113.1, 112.6, 67.1, 65.7, 47.4, 44.8, 38.1, 36.8, 36.6, 30.0, 25.2, 25.2, 21.7, 18.5, 16.2. HRMS (AP-ESI) Calcd. for C<sub>28</sub>H<sub>33</sub>O<sub>7</sub>: 493.2232 [M &#x02013; H]<sup>&#x02212;</sup>. Found: 493.2226.</p><p><italic>Compound</italic>
<bold><italic>18</italic></bold>. White solid; mp: 112&#x02013;113&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.12 (dt, <italic>J</italic>&#x02009;=&#x02009;21.5, 10.8&#x02009;Hz, 1H), 7.13 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 1H), 6.65 (dd, <italic>J</italic>&#x02009;=&#x02009;8.6, 2.4&#x02009;Hz, 1H), 6.52 (d, <italic>J</italic>&#x02009;=&#x02009;2.4&#x02009;Hz, 1H), 5.33 (s, 1H), 4.70 (dd, <italic>J</italic>&#x02009;=&#x02009;8.9, 4.3&#x02009;Hz, 1H), 4.33 (t, <italic>J</italic>&#x02009;=&#x02009;4.3&#x02009;Hz, 1H), 2.96&#x02013;2.79 (m, 2H), 2.34&#x02013;2.17 (m, 2H), 1.93&#x02013;1.80 (m, 3H), 1.80&#x02013;1.70 (m, 2H), 1.54 (q, <italic>J</italic>&#x02009;=&#x02009;6.9&#x02009;Hz, 2H), 1.31 (s, 3H), 1.22 (d, <italic>J</italic>&#x02009;=&#x02009;6.7&#x02009;Hz, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.0, 165.7, 156.1, 153.1, 142.0, 136.6, 130.1, 129.8, 125.5, 115.0, 114.4, 113.1, 112.7, 65.8, 64.2, 47.4, 44.7, 38.1, 36.7, 36.6, 30.0, 25.2, 21.7, 18.5, 16.2. HRMS (AP-ESI) Calcd. for C<sub>27</sub>H<sub>29</sub>O<sub>7</sub>: 465.1919 [M &#x02013; H]<sup>&#x02212;</sup>. Found: 465.1928.</p><p><italic>Compound</italic>
<bold><italic>19</italic></bold>. White solid; mp: 113&#x02013;114&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, <italic>d<sub>6</sub></italic>-DMSO) &#x003b4; 8.50 (s, 1H), 8.20 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 8.14 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 7.65 (t, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, 1H), 7.16 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 6.75 (dd, <italic>J</italic>&#x02009;=&#x02009;8.6, 2.1&#x02009;Hz, 1H), 6.63 (s, 1H), 4.62 (s, 2H), 4.30 (s, 2H), 2.87&#x02013;2.66 (m, 3H), 2.28 (d, <italic>J</italic>&#x02009;=&#x02009;12.4&#x02009;Hz, 1H), 2.01 (d, <italic>J</italic>&#x02009;=&#x02009;11.7&#x02009;Hz, 1H), 1.45&#x02013;1.19 (m, 4H), 1.16 (s, 3H), 1.1 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 183.0, 169.7, 165.1, 153.1, 142.0, 136.6, 130.1, 129.8, 125.5, 118.0, 117.4, 116.1, 115.7, 65.8, 64.2, 47.4, 45.7, 38.1, 36.7, 36.6, 30.0, 29.2, 28.7, 24.7, 19.7. HRMS (AP-ESI) Calcd. for C<sub>27</sub>H<sub>29</sub>O<sub>7</sub>: 465.1919 [M &#x02013; H]<sup>&#x02212;</sup>. Found: 465.1926.</p><p><italic>Compound</italic>
<bold><italic>20</italic></bold>. White solid; mp: 102&#x02013;103&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.21 (dd, <italic>J</italic>&#x02009;=&#x02009;7.8, 1.4&#x02009;Hz, 1H), 7.63&#x02013;7.51 (m, 1H), 7.21&#x02013;7.03 (m, 3H), 6.78 (dd, <italic>J</italic>&#x02009;=&#x02009;8.6, 2.5&#x02009;Hz, 1H), 6.63 (d, <italic>J</italic>&#x02009;=&#x02009;2.3&#x02009;Hz, 1H), 4.63&#x02013;4.51 (m, 2H), 4.42&#x02013;4.30 (m, 2H), 3.01&#x02013;2.78 (m, 3H), 2.27 (dd, <italic>J</italic>&#x02009;=&#x02009;31.5, 12.4&#x02009;Hz, 3H), 1.95&#x02013;1.81 (m, 4H), 1.81&#x02013;1.70 (s, 3H), 1.28 (d, <italic>J</italic>&#x02009;=&#x02009;13.2&#x02009;Hz, 4H), 1.24&#x02013;1.16 (m, 4H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 184.8, 166.0, 157.3, 155.5, 143.0, 136.6, 134.9, 133.9, 125.6, 122.7, 118.5, 114.2, 113.4, 112.7, 68.5, 65.3, 47.4, 44.7, 38.0, 36.7, 30.2, 25.2, 21.6, 18.5, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>31</sub>O<sub>6</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 439.2115, found 439.2123.</p><p><italic>Compound</italic>
<bold><italic>21</italic></bold>. White solid; mp: 112&#x02013;113&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.19 (dd, <italic>J</italic>&#x02009;=&#x02009;7.8, 1.7&#x02009;Hz, 1H), 7.62&#x02013;7.52 (m, 1H), 7.20&#x02013;7.03 (m, 3H), 6.77 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.6&#x02009;Hz, 1H), 6.61 (d, <italic>J</italic>&#x02009;=&#x02009;2.5&#x02009;Hz, 1H), 5.32 (s, 1H), 4.44 (t, <italic>J</italic>&#x02009;=&#x02009;6.0&#x02009;Hz, 2H), 4.17 (t, <italic>J</italic>&#x02009;=&#x02009;5.4&#x02009;Hz, 2H), 2.97&#x02013;2.84 (m, 3H), 2.43&#x02013;2.34 (m, 2H), 2.30 (d, <italic>J</italic>&#x02009;=&#x02009;12.6&#x02009;Hz, 1H), 2.23 (d, <italic>J</italic>&#x02009;=&#x02009;12.3&#x02009;Hz, 1H), 1.92&#x02013;1.80 (m, 4H), 1.80&#x02013;1.69 (m, 3H),1.54&#x02013;1.28 (m, 3H),1.25 (s, 3H),1.25 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 184.9, 166.3, 157.7, 156.1, 142.4, 136.4, 135.0, 133.8, 125.5, 122.0, 117.8, 113.8, 112.7, 112.4, 67.5, 64.5, 47.4, 44.7, 38.1, 36.7, 36.6, 30.2, 29.1, 25.2, 21.6, 18.5, 16.2. HRMS: m/z calcd for C<sub>27</sub>H<sub>33</sub>O<sub>6</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 453.2272, found 453.2286.</p><p><italic>Compound</italic>
<bold><italic>22</italic></bold>. White solid; mp: 156&#x02013;157&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.96&#x02013;7.90 (m, 1H), 7.76&#x02013;7.68 (m, 1H), 7.60 (tt, <italic>J</italic>&#x02009;=&#x02009;13.6, 6.8&#x02009;Hz, 2H), 5.27 (dd, <italic>J</italic>&#x02009;=&#x02009;25.2, 11.3&#x02009;Hz, 2H), 4.39 (d, <italic>J</italic>&#x02009;=&#x02009;11.0&#x02009;Hz, 1H), 3.92 (d, <italic>J</italic>&#x02009;=&#x02009;11.1&#x02009;Hz, 1H), 2.96 (d, <italic>J</italic>&#x02009;=&#x02009;29.7&#x02009;Hz, 1H), 2.64&#x02013;2.50 (m, 1H), 2.40 (dd, <italic>J</italic>&#x02009;=&#x02009;6.5, 3.5&#x02009;Hz, 1H), 2.36 (dd, <italic>J</italic>&#x02009;=&#x02009;6.4, 3.5&#x02009;Hz, 1H), 2.15&#x02013;2.07 (m, 1H), 2.02&#x02013;1.87 (m, 6H), 1.77 (dt, <italic>J</italic>&#x02009;=&#x02009;13.0, 8.3&#x02009;Hz, 3H), 1.69&#x02013;1.60 (m, 2H), 1.45 (s, 4H), 1.29 (t, <italic>J</italic>&#x02009;=&#x02009;12.0&#x02009;Hz, 5H), 1.23&#x02013;1.15 (m, 6H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.2, 171.8, 158.7, 156.1, 142.5, 136.5, 130.6, 129.6, 125.4, 123.0, 121.2, 115.2, 114.3, 112.7, 66.8, 66.3, 53.4, 47.4, 44.7, 38.1, 36.6, 30.2, 25.2, 21.7, 18.5, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>31</sub>O<sub>6</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 439.2115, found 439.2120.</p><p><italic>Compound</italic>
<bold><italic>23</italic></bold>. White solid; mp: 158&#x02013;159&#x02009;&#x000b0;C; <sup>1</sup>HNMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.74 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x02009;Hz, 1H), 7.68 (s, 1H), 7.40 (t, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.25&#x02013;7.16 (m, 2H), 6.82&#x02013;6.76 (m, 1H), 6.65 (s, 1H), 5.33 (s, 1H), 4.36 (dd, <italic>J</italic>&#x02009;=&#x02009;13.3, 3.8&#x02009;Hz, 3H), 3.02&#x02013;2.83 (m, 2H), 2.29 (dd, <italic>J</italic>&#x02009;=&#x02009;23.2, 12.4&#x02009;Hz, 2H), 1.87 (dd, <italic>J</italic>&#x02009;=&#x02009;21.6, 11.8&#x02009;Hz, 2H), 1.77 (t, <italic>J</italic>&#x02009;=&#x02009;11.0&#x02009;Hz, 2H), 1.57 (dd, <italic>J</italic>&#x02009;=&#x02009;12.7, 6.6&#x02009;Hz, 1H), 1.48&#x02013;1.32 (s, 3H), 1.32&#x02013;1.25 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.2, 171.8, 158.7, 156.1, 142.5, 136.5, 130.6, 129.6, 125.4, 123.0, 121.2, 115.2, 114.3, 112.7, 66.8, 66.3, 47.4, 44.7, 38.1, 36.7, 30.2, 25.2, 21.7, 18.5, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>31</sub>O<sub>6</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 439.2115, found 439.2118.</p><p><italic>Compound</italic>
<bold><italic>24</italic></bold>. Yellow oil; mp: 145&#x02013;146&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.21 (dd<italic>, J</italic>&#x02009;=&#x02009;7.8, 1.8&#x02009;Hz, 1H), 7.67&#x02013;7.56 (m, 1H), 7.28 (t<italic>, J</italic>&#x02009;=&#x02009;4.4&#x02009;Hz, 1H), 7.22 (t, <italic>J</italic>&#x02009;=&#x02009;7.2&#x02009;Hz, 1H), 7.04 (d, <italic>J</italic>&#x02009;=&#x02009;8.3&#x02009;Hz, 1H), 6.92 (dd, <italic>J</italic>&#x02009;=&#x02009;8.6, 2.5&#x02009;Hz, 1H), 6.83 (d, <italic>J</italic>&#x02009;=&#x02009;2.5&#x02009;Hz, 1H), 5.06 (s, 2H), 1.85&#x02013;1.76 (m, 2H),1.76&#x02013;1.68 (m, 2H),1.68&#x02013;1.62 (m, 2H), 1.66&#x02013;1.40 (m, 3H), 1.31 (s, 3H), 1.23 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 184.6, 166.5, 166.1, 156.5, 147.8, 147.3, 137.0, 134.9, 134.1, 125.7, 123.1, 120.9, 119.0, 118.2, 113.1, 66.4, 47.30, 44.3, 37.9, 37.1, 36.7, 29.9, 25.1, 21.4, 18.4, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>28</sub>O<sub>7</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 454.1908, found 454.1902.</p><p><italic>Compound</italic>
<bold><italic>25</italic></bold>. White solid; mp: 138&#x02013;139&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.13&#x02013;8.05 (m, 1H), 7.59 (t, <italic>J</italic>&#x02009;=&#x02009;7.4&#x02009;Hz, 1H), 7.46 (t, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, 1H), 7.19 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 6.78 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.6&#x02009;Hz, 1H), 6.64 (d, <italic>J</italic>&#x02009;=&#x02009;2.5&#x02009;Hz, 1H), 4.67 (t, <italic>J</italic>&#x02009;=&#x02009;9.2&#x02009;Hz, 1H), 4.30 (t, <italic>J</italic>&#x02009;=&#x02009;9.6&#x02009;Hz, 1H), 3.04&#x02013;2.83 (m, 2H), 2.39&#x02013;2.14 (m, 2H), 1.95&#x02013;1.69 (m, 5H), 1.65&#x02013;1.48 (m, 2H), 1.31 (s, 3H), 1.23 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.0, 166.6, 156.2, 142.4, 136.5, 133.1, 129.9, 129.8, 128.4, 125.4, 125.4, 114.2, 112.7, 65.9, 63.6, 47.4, 44.7, 38.1, 36.7, 30.2, 26.9, 25.2, 21.7, 18.5, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>30</sub>O<sub>5</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 424.2166, found 224.2199.</p><p><italic>Compound</italic>
<bold><italic>26</italic></bold>. White solid; mp: 111&#x02013;112&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 10.69 (s, 1H), 7.86 (dd, <italic>J</italic>&#x02009;=&#x02009;8.0, 1.7&#x02009;Hz, 1H), 7.51&#x02013;7.43 (m, 1H), 7.19 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 7.00 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x02009;Hz, 1H), 6.92&#x02013;6.85 (m, 1H), 6.77 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.7&#x02009;Hz, 1H), 6.63 (d, <italic>J</italic>&#x02009;=&#x02009;2.7&#x02009;Hz, 1H), 4.74&#x02013;4.63 (m, 2H), 4.33&#x02013;4.26 (m, 2H), 2.31 (d, <italic>J</italic>&#x02009;=&#x02009;12.7&#x02009;Hz, 1H), 2.23 (dd, <italic>J</italic>&#x02009;=&#x02009;12.4, 1.9&#x02009;Hz, 1H), 1.97&#x02013;1.68 (m, 5H), 1.60&#x02013;1.41 (m,3H), 1.31 (s, 3H), 1.22 (s, 3H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 184.8, 170.0, 161.7, 156.1, 142.6, 136.5, 135.9, 130.2, 125.5, 119.2, 117.6, 114.3, 112.8, 112.3, 65.7, 63.8, 60.4, 47.4, 44.7, 38.1, 36.8, 36.7, 30.2, 25.2, 21.7, 18.5, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>30</sub>O<sub>6</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 440.2115, found 440.2146.</p><p><italic>Compound</italic>
<bold><italic>27</italic></bold>. White solid; mp: 128&#x02013;129&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.09&#x02013;8.06 (m, 1H), 7.58 (t, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 7.48&#x02013;7.43 (m, 1H), 7.19 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 1H), 6.78 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.8&#x02009;Hz, 1H), 6.66&#x02013;6.64 (m, 1H), 4.67 (t, <italic>J</italic>&#x02009;=&#x02009;9.2&#x02009;Hz, 1H), 4.30 (t, <italic>J</italic>&#x02009;=&#x02009;9.2&#x02009;Hz, 1H), 1.90&#x02013;1.83 (m, 4H), 1.83&#x02013;1.73 (m, 3H),1.66&#x02013;1.42 (m, 3H), 1.31 (s, 3H), 1.22 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 183.0, 166.0, 154.2, 140.5, 134.5, 133.3, 131.4, 130.0, 126.8, 113.8, 111.4, 66.4, 63.9, 51.5, 43.9, 38.4, 37.6, 37.4, 30.1, 28.1, 24.7, 20.1, 19.7. HRMS: m/z calcd for C<sub>26</sub>H<sub>29</sub>ClO<sub>5</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 457.1776, found 457.1774.</p><p><italic>Compound</italic>
<bold><italic>28</italic></bold>. White solid; mp: 126&#x02013;127&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.88 (dd, <italic>J</italic>&#x02009;=&#x02009;8.1, 1.4&#x02009;Hz, 1H), 7.33&#x02013;7.25 (m, 1H), 7.18 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 6.77 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.7&#x02009;Hz, 1H), 6.71&#x02013;6.60 (m, 3H), 4.62 (t, <italic>J</italic>&#x02009;=&#x02009;9.6, 2H), 4.28 (t, <italic>J</italic>&#x02009;=&#x02009;9.6, 2H), 3.01&#x02013;2.83 (m, 2H), 2.36&#x02013;2.18 (m, 2H), 1.96&#x02013;1.82 (m, 4H), 1.82&#x02013;1.73 (m, 2H), 1.31 (s, 3H), 1.22 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 168.0, 156.2, 150.5, 142.4, 136.4, 134.2, 131.5, 125.4, 116.7, 116.3, 114.3, 112.8, 110.6, 66.0, 62.9, 47.4, 44.8, 38.1, 36.8, 36.7, 30.2, 25.2, 21.7, 18.5, 16.2. HRMS: m/z calcd for C<sub>26</sub>H<sub>31</sub>NO<sub>5</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 439.2275, found 439.2271.</p><p><italic>Compound</italic>
<bold><italic>29</italic></bold>. White solid; mp: 158&#x02013;159&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.79 (d, <italic>J</italic>&#x02009;=&#x02009;4.7&#x02009;Hz, 1H), 8.14 (d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H), 7.86 (t, <italic>J</italic>&#x02009;=&#x02009;7.8&#x02009;Hz, 1H), 7.56&#x02013;7.47 (m, 1H), 7.16 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 1H), 6.74 (s, 1H), 6.61 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x02009;Hz, 1H), 4.76 (t, <italic>J</italic>&#x02009;=&#x02009;9.2&#x02009;Hz, 1H), 4.33 (t, <italic>J</italic>&#x02009;=&#x02009;9.2&#x02009;Hz, 1H), 3.01&#x02013;2.83 (m, 2H), 2.36&#x02013;2.18 (m, 2H), 1.95&#x02013;1.83 (m, 4H), 1.83&#x02013;1.70 (m, 2H), 1.31 (s, 3H), 1.22 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 168.7, 155.9, 142.7, 136.5, 125.5, 114.2, 112.6, 65.4, 64.6, 56.4, 53.5, 47.3, 44.8, 43.8, 38.2, 36.8, 36.7, 30.2, 25.7, 25.2, 21.7, 18.6, 16.4. HRMS: m/z calcd for C<sub>25</sub>H<sub>29</sub>NO<sub>5</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 424.2118, found 424.2115.</p><p><italic>Compound</italic>
<bold><italic>30</italic></bold>. White solid; mp: 161&#x02013;162&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 8.04 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 7.52 (t, <italic>J</italic>&#x02009;=&#x02009;7.5&#x02009;Hz, 1H), 7.38 (t, <italic>J</italic>&#x02009;=&#x02009;7.3&#x02009;Hz, 1H), 7.30 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x02009;Hz, 1H), 7.16 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 1H), 6.75 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.6&#x02009;Hz, 1H), 6.61 (d, <italic>J</italic>&#x02009;=&#x02009;2.5&#x02009;Hz, 1H), 4.68&#x02013;4.61 (m, 2H), 4.33&#x02013;4.22 (m, 2H), 4.06 (s, 2H), 2.94&#x02013;2.70 (m, 2H), 2.29 (d, <italic>J</italic>&#x02009;=&#x02009;12.5&#x02009;Hz, 1H), 2.20 (d, <italic>J</italic>&#x02009;=&#x02009;13.9&#x02009;Hz, 1H), 1.94&#x02013;1.84 (m, 2H), 1.84&#x02013;1.68 (m, 3H), 1.60&#x02013;1.41 (m, 2H), 1.28 (s, 3H), 1.20 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.1, 177.0, 167.3, 156.1, 142.5, 136.4, 135.4, 132.8, 132.4 131.3, 129.4 127.7, 125.4, 114.2, 112.8, 65.7, 63.8, 47.4, 44.7, 40.7, 38.1, 36.7, 36.6, 30.1, 25.2, 21.6, 18.5, 16.2. HRMS: m/z calcd for C<sub>28</sub>H<sub>32</sub>O<sub>7</sub> [M&#x02009;+&#x02009;Na]<sup>+</sup> 504.2221, found 504.2071</p><p><italic>Compound</italic>
<bold><italic>31</italic></bold>. White solid; mp: 116&#x02013;117&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.15 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x02009;Hz, 1H), 6.71 (dd, <italic>J</italic>&#x02009;=&#x02009;8.7, 2.6&#x02009;Hz, 1H), 6.57 (s, 1H), 4.48&#x02013;4.31 (m, 2H), 4.20&#x02013;3.89 (m, 2H), 3.03&#x02013;2.73 (m, 4H), 2.25 (dd, <italic>J</italic>&#x02009;=&#x02009;32.2, 11.8&#x02009;Hz, 2H), 2.04 (s, 1H), 1.88&#x02013;1.82 (m, 2H), 1.82&#x02013;1.76 (m, 2H), 1.76&#x02013;1.71 (m, 2H), 1.55&#x02013;1.36 (m, 5H), 1.28 (s, 3H), 1.20 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 185.1, 179.9, 173.6, 156.1, 142.4, 136.3, 125.3, 114.3, 114.2, 112.8, 112.7, 65.8, 63.0, 60.4, 47.3, 44.7, 42.5, 42.4, 38.1, 36.7, 36.6, 30.1, 25.2, 21.6, 21.1, 18.5, 16.2, 14.2. HRMS: m/z calcd for C<sub>27</sub>H<sub>36</sub>O<sub>7</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 474.2534, found 474.2570.</p><p><italic>Compound</italic>
<bold><italic>32</italic></bold>. White solid; mp: 109&#x02013;110&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.15 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 6.69 (d, <italic>J</italic>&#x02009;=&#x02009;6.9&#x02009;Hz, 1H), 6.55 (s, 1H), 4.54 (s, 2H), 4.15 (s, 2H), 3.51 (s, 1H), 2.84 (s, 2H), 2.37&#x02013;1.89 (m, 5H), 1.75 (m, 6H), 1.59&#x02013;1.36 (m, 3H), 1.28 (s, 3H), 1.18 (s, 3H)<sup>. 13&#x02009;</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 168.7, 155.9, 142.7, 136.5, 125.5, 114.2, 112.6, 65.4, 64.6, 56.4, 53.5, 47.3, 44.8, 43.8, 38.2, 36.8, 36.7, 30.2, 25.7, 25.2, 21.7, 18.6, 16.4. HRMS: m/z calcd for C<sub>24</sub>H<sub>33</sub>NO<sub>5</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 417.2431, found 417.2462.</p><p><italic>Compound</italic>
<bold><italic>33</italic></bold>. White solid; mp: 48&#x02013;49&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 7.16 (d, <italic>J</italic>&#x02009;=&#x02009;10.0&#x02009;Hz, 1H), 6.72 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x02009;Hz, 1H), 6.58 (s, 1H), 4.39&#x02013;3.66 (m, 6H), 3.34&#x02013;3.29 (m, 2H), 2.99&#x02013;2.78 (m, 2H), 2.38&#x02013;2.05 (m, 4H), 1.80&#x02013;1.63 (m, 4H), 1.54&#x02013;1.38 (m, 2H), 1.26 (s, 3H), 1.20 (s, 2H). <sup>13</sup>C NMR (300&#x02009;MHz, CDCl<sub>3</sub>) &#x003b4; 183.4, 156.2, 142.6, 136.5, 125.4, 114.2, 112.5, 69.1, 61.4, 53.1, 47.3, 45.8, 44.9, 38.2, 36.8, 36.7, 30.2, 25.2, 21.6, 18.6, 16.4. HRMS: m/z calcd for C<sub>25</sub>H<sub>35</sub>NO<sub>5</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 431.2588, found 431.2615.</p><p><italic>Compound</italic>
<bold><italic>34</italic></bold>. White solid; mp: 189&#x02013;190&#x02009;&#x000b0;C; <sup>1</sup>H NMR (400&#x02009;MHz, <italic>d<sub>6</sub></italic>-DMSO) &#x003b4; 12.72 (s, 2H), 8.67 (d, <italic>J</italic>&#x02009;=&#x02009;4.9&#x02009;Hz, 2H), 8.23 (dd, <italic>J</italic>&#x02009;=&#x02009;8.4, 4.8&#x02009;Hz, 2H), 8.04 (dd, <italic>J</italic>&#x02009;=&#x02009;14.0, 8.7&#x02009;Hz, 2H), 7.14 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x02009;Hz, 1H), 6.76 (d, <italic>J</italic>&#x02009;=&#x02009;10.5&#x02009;Hz, 1H), 6.64 (s, 1H), 4.66 (s, 2H), 4.34 (s, 2H), 2.25 (d, <italic>J</italic>&#x02009;=&#x02009;12.0&#x02009;Hz, 1H), 2.01 (d, <italic>J</italic>&#x02009;=&#x02009;11.6&#x02009;Hz, 1H), 1.78&#x02013;1.48 (m, 2H), 1.15 (s, 3H), 1.09 (s, 3H). <sup>13&#x02009;</sup>C NMR (300&#x02009;MHz, <italic>d<sub>6</sub></italic>-DMSO) &#x003b4; 179.9, 167.6, 166.0, 156.3, 142.6, 136.3, 134.8, 134.5, 130.9, 130.7, 130.6, 130.4, 130.3, 129.3, 126.5, 126.0, 125.8, 114.5, 113.2, 66.1, 64.4, 46.8, 45.3, 38.3, 36.7, 30.2, 25.3, 21.5, 18.6, 16.8. HRMS: m/z calcd for C<sub>31</sub>H<sub>32</sub>O<sub>7</sub> [M&#x02009;+&#x02009;H]<sup>+</sup> 517.2221, found 517.2231.</p></sec></sec><sec id="s0021"><label>4.2.</label><title>Biological assays</title><sec id="s0022"><label>4.2.1.</label><title>PTP1B inhibition assay</title><p>The inhibitory assay was performed using human PTP1B (purchased from Sigma) and p-nitrophenylphosphate (pNPP) as substrate by UV absorption. 400&#x02009;nmol pNPP were dissolved in H<sub>2</sub>O and 48&#x02009;&#x003bc;L of the solution was added to a 100&#x02009;&#x003bc;L reaction. The indicated amount of synthetic compounds was diluted in DMSO at a concentration of 5&#x02009;mM. The PTP1B was diluted in pH 7.2 buffer contained 50&#x02009;mM HEPES, 3&#x02009;mM dithiothreitol, 2&#x02009;mM EDTA and 100&#x02009;mM NaCl. About 50&#x02009;&#x003bc;L PTP1B dilution was added, and the mixture incubated at 37&#x02009;&#x000b0;C for 30&#x02009;min. 1N NaOH was added to terminate the reaction. UV&#x02013;Vis absorption was detected at 410&#x02009;nm using a Tecan Infinite M1000 plate reader.</p></sec><sec id="s0023"><label>4.2.2.</label><title>Glucose uptake assay</title><p>HepG2 cells were grown in DMEM with 10% foetal bovine serum, 100&#x02009;mg/mL of streptomycin, and 100&#x02009;U/mL of penicillin, in a humidified atmosphere of 5% CO<sub>2</sub> at 37&#x02009;&#x000b0;C. HepG2 cells were cultured in 96-well tuft plates. After overnight incubation, the cells were serum starved for 12&#x02009;h. Then, the cells were treated with insulin (6&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;6</sup>&#x02013;5&#x02009;&#x000d7;&#x02009;10<sup>&#x02212;5&#x02009;</sup>mmol/L) for 0&#x02013;60&#x02009;h to induce insulin resistance. HepG2 cells were then cultured for another 24&#x02009;h in the compound (40&#x02009;&#x003bc;M) or rosiglitazone (10&#x02009;&#x003bc;M, available from Bied Pharmaceutical Technology Co., Ltd., Shanghai, China) containing DMEM. After cultivation, the glucose content was determined by the glucose oxidase method (the glucose analysis kit was purchased from Rongsheng Biopharmaceutical Co., Ltd., Shanghai, China). The sample and the kit working solution were thoroughly mixed at a ratio of 1:100, and placed in a 37&#x02009;&#x000b0;C water bath for 15&#x02009;min. The absorbance was measured at 506&#x02009;nm using a microplate reader (SpectraMax i3x, Molecular Devices). The residual glucose concentration is expressed as <italic>A</italic><sub>X</sub>/<italic>A</italic><sub>0</sub> &#x000d7; 5.55&#x02009;mmol/L (<italic>A</italic><sub>X</sub>: OD value of sample; <italic>A</italic><sub>0</sub>: OD value of glucose standard solution).</p></sec><sec id="s0024"><label>4.2.3.</label><title>Animal experiment</title><p>During the experiment, the male Kunming mice with 25&#x02013;30&#x02009;g body weight were fasted but received water prior to induction of diabetes. 110&#x02009;mg/kg of nicotinamide and 65&#x02009;mg/kg of streptozotocin (Macklin in Biochemical Technology Co., Ltd., Shanghai, China) were dissolved in pH 4.5 citrate buffer and intraperitoneally administrated to induce NIDDM mice model. The mice were intraperitoneally administered with a compound or rosiglitazone (100&#x02009;mg/kg) dissolved in saline containing 1% DMSO and 10% Tween 80. Hyperglycaemia was confirmed by a plasma glucose increase of more than 4.5&#x02009;mmol/L measured by a blood glucose metre (Sinocare GA-3, Changsha, China). Glucose concentrations from the tail of the mice were measured at 0, 0.5, 1, 2, 3 and 4&#x02009;h by the blood glucose metre. Calculate the percentage of blood glucose by using the following formula: variation of glycaemia% = (<italic>A</italic><sub>X</sub> &#x02212; <italic>A</italic><sub>0</sub>)/<italic>A</italic><sub>0</sub> &#x000d7; 100% (<italic>A</italic><sub>X</sub>: blood glucose at selected time; <italic>A</italic><sub>0</sub>: initial blood glucose).</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM8822"><caption><title>Supplemental Material</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="IENZ_A_1690481_SM8822.pdf" orientation="portrait" id="d37e189" position="anchor"/></supplementary-material></sec></body><back><sec id="s0025"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Magliano</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group>
<article-title>The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives</article-title>. <source>Nat Rev Endocrinol</source>
<year>2012</year>;<volume>8</volume>:<fpage>228</fpage>&#x02013;<lpage>36</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dieren</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Beulens</surname><given-names>JWJ</given-names></name>, <name name-style="western"><surname>van der Schouw</surname><given-names>YT</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The global burden of diabetes and its complications: an emerging pandemic</article-title>. <source>Eur J Cardiov Prev R</source>
<year>2010</year>;<volume>17</volume>:<fpage>S3</fpage>&#x02013;<lpage>S8</lpage>.</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinman</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wanner</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lachin</surname><given-names>JM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Investigators, empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes</article-title>. <source>New Engl J Med</source>
<year>2015</year>;<volume>373</volume>:<fpage>2117</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">26378978</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Catanzaro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lorenzetti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Allegri</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibiting insulin resistance mechanisms by DTS phytocompound: an experimental study on metabolic syndrome-prone adipocytes</article-title>. <source>Acta bio-medica Atenei Parmensis</source>
<year>2012</year>;<volume>83</volume>:<fpage>95</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">23393916</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonner</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kerr-Conte</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gmyr</surname><given-names>V</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion</article-title>. <source>Nat Med</source>
<year>2015</year>;<volume>21</volume>:<fpage>512</fpage>&#x02013;<lpage>U139</lpage>.<pub-id pub-id-type="pmid">25894829</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Bethel</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Armstrong</surname><given-names>PW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes</article-title>. <source>New Engl J Med</source>
<year>2015</year>;<volume>373</volume>:<fpage>232</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">26052984</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials</article-title>. <source>Obes Rev</source>
<year>2019</year>;<volume>20</volume>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30230172</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gouni-Berthold</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Berthold</surname><given-names>HK</given-names></name></person-group>
<article-title>Pharmacologic therapy for cardiovascular risk reduction in patients with the metabolic syndrome</article-title>. <source>Curr Pharm Des</source>
<year>2014</year>;<volume>20</volume>:<fpage>5025</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">24320031</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajasurya</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Anjum</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Surani</surname><given-names>S</given-names></name></person-group>
<article-title>Metformin use and metformin-associated lactic acidosis in intensive care unit patients with diabetes</article-title>. <source>Cureus</source>
<year>2019</year>;<volume>11</volume>:UNSP <fpage>e4739</fpage>.<pub-id pub-id-type="pmid">31355098</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Liraglutide exerts antidiabetic effect via PTP1B and PI3K/Akt2 signaling pathway in skeletal muscle of KKAy mice</article-title>. <source>Int J Endocrinol</source>
<year>2014</year>;<volume>9</volume>:<fpage>312452</fpage>.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panzhinskiy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hua</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Culver</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Endoplasmic reticulum stress upregulates protein tyrosine phosphatase 1B and impairs glucose uptake in cultured myotubes</article-title>. <source>Diabetologia</source>
<year>2013</year>;<volume>56</volume>:<fpage>598</fpage>&#x02013;<lpage>607</lpage>.<pub-id pub-id-type="pmid">23178931</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Meng</surname><given-names>TC</given-names></name></person-group>
<article-title>Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases</article-title>. <source>J Biol Chem</source>
<year>2010</year>;<volume>285</volume>:<fpage>7919</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">20064934</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elchebly</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Payette</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Michaliszyn</surname><given-names>E</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene</article-title>. <source>Science</source>
<year>1999</year>;<volume>283</volume>:<fpage>1544</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">10066179</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delibegovic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zimmer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kauffman</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Liver-specific deletion of protein-tyrosine phosphatase 1B (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic reticulum stress</article-title>. <source>Diabetes</source>
<year>2009</year>;<volume>58</volume>:<fpage>590</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19074988</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bence</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Delibegovic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Neuronal PTP1B regulates body weight, adiposity and leptin action</article-title>. <source>Nat Med</source>
<year>2006</year>;<volume>12</volume>:<fpage>917</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">16845389</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Ruiz</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Vieira</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Garcia-Roves</surname><given-names>PM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Protein tyrosine phosphatase-1B modulates pancreatic beta-cell mass</article-title>. <source>PLoS One</source>
<year>2014</year>;<volume>9</volume>:<fpage>e90344</fpage>.<pub-id pub-id-type="pmid">24587334</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Xi</surname><given-names>YN</given-names></name>, <name name-style="western"><surname>Bettaieb</surname><given-names>A</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Disruption of protein-tyrosine phosphatase 1B expression in the pancreas affects beta-cell function</article-title>. <source>Endocrinology</source>
<year>2014</year>;<volume>155</volume>:<fpage>3329</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">24956127</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for type 2 diabetes</article-title>. <source>Fut Med Chem</source>
<year>2016</year>;<volume>8</volume>:<fpage>1239</fpage>&#x02013;<lpage>58</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>PTP1B markedly promotes breast cancer progression and is regulated by miR-193a-3p</article-title>. <source>Febs J</source>
<year>2019</year>;<volume>286</volume>:<fpage>1136</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">30548198</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Ruiz</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Blanes Ruiz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rada</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Protein tyrosine phosphatase 1B deficiency protects against hepatic fibrosis by modulating NADPH oxidases</article-title>. <source>Redox Bio</source>
<year>2019</year>;<volume>26</volume>:<fpage>101263</fpage>.<pub-id pub-id-type="pmid">31299613</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of tryptophan-derived rhodanine derivatives as PTP1B inhibitors and anti-bacterial agents</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>172</volume>:<fpage>163</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">30978561</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2007</year>;<volume>104</volume>:<fpage>19767</fpage>&#x02013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">18056643</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olivier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hsiung</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Chuang</surname><given-names>LM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Single nucleotide polymorphisms in protein tyrosine phosphatase 1 beta (PTPN1) are associated with essential hypertension and obesity</article-title>. <source>Hum Mol Genet</source>
<year>2004</year>;<volume>13</volume>:<fpage>1885</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">15229188</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Combs</surname><given-names>AP</given-names></name></person-group>
<article-title>Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>2333</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">20000419</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Liang</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>YW</given-names></name></person-group>
<article-title>Natural products possessing protein tyrosine phosphatase 1B (PTP1B) inhibitory activity found in the last decades</article-title>. <source>Acta Pharmacol Sin</source>
<year>2012</year>;<volume>33</volume>:<fpage>1217</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">22941286</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bai</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Therapeutic mechanisms of herbal medicines against insulin resistance: a review</article-title>. <source>Front Pharmacol</source>
<year>2019</year>;<volume>10</volume>:<fpage>661</fpage>.<pub-id pub-id-type="pmid">31258478</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>N</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Natural and semisynthetic protein tyrosine phosphatase 1B (PTP1B) inhibitors as anti-diabetic agents</article-title>. <source>RSC Adv</source>
<year>2015</year>;<volume>5</volume>:<fpage>48822</fpage>&#x02013;<lpage>834</lpage>.</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of oleanolic acid derivatives as inhibitors of protein tyrosine phosphatase 1B</article-title>. <source>J Nat Prod</source>
<year>2010</year>;<volume>73</volume>:<fpage>1743</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">20964318</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>QL</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>JL</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of raddeanin A, a triterpene saponin isolated from <italic>Anemone raddeana</italic></article-title>. <source>Chem Pharm Bull</source>
<year>2014</year>;<volume>62</volume>:<fpage>779</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">25087630</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>He</surname><given-names>YX</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of oleanane triterpenoid with <italic>gamma</italic>-lactone functionality in ring C</article-title>. <source>Chem J Chin Univ</source>
<year>2012</year>;<volume>33</volume>:<fpage>969</fpage>&#x02013;<lpage>75</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pei</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of oleanolic disaccharide derivatives</article-title>. <source>Chin Chem Lett</source>
<year>2012</year>;<volume>23</volume>:<fpage>403</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>F</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of oleanolic acid derivatives as antitumor agents</article-title>. <source>J Asian Nat Prod Res</source>
<year>2012</year>;<volume>14</volume>:<fpage>355</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">22375874</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>YW</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and <italic>alpha</italic>-glucosidase inhibitory activity of oleanolic acid derivatives</article-title>. <source>J Asian Nat Prod Res</source>
<year>2010</year>;<volume>12</volume>:<fpage>20</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">20390739</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moretto</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Kirincich</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>WX</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors</article-title>. <source>Bioorg Med Chem</source>
<year>2006</year>;<volume>14</volume>:<fpage>2162</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">16303309</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puius</surname><given-names>YA</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1997</year>;<volume>94</volume>:<fpage>13420</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">9391040</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abad</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arno</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Domingo</surname><given-names>LR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of (+)-podocarp-8(14)-en-13-one and methyl-(+)-13-oxo-podocarp-8(14)-en-18-oate from abietic acid</article-title>. <source>Tetrahedron</source>
<year>1985</year>;<volume>41</volume>:<fpage>4937</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez-Manzaneda</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Chahboun</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Guardia</surname><given-names>JJ</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>New route to 15-hydroxydehydroabietic acid derivatives: application to the first synthesis of some bioactive abietane and nor-abietane type terpenoids</article-title>. <source>Tetrahedron Lett</source>
<year>2006</year>;<volume>47</volume>:<fpage>2577</fpage>&#x02013;<lpage>80</lpage>.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Correa-Royero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Agudelo</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of abietic acid derivatives</article-title>. <source>Eur J Med Chem</source>
<year>2009</year>;<volume>44</volume>:<fpage>2468</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">19217699</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boger</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Coleman</surname><given-names>RS</given-names></name></person-group>
<article-title>Benzylic hydroperoxide rearrangement - observations on a viable and convenient alternative to the Baeyer-Villiger rearrangement</article-title>. <source>J Org Chem</source>
<year>1986</year>;<volume>51</volume>:<fpage>5436</fpage>&#x02013;<lpage>39</lpage>.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Ravn</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Coates</surname><given-names>RM</given-names></name></person-group>
<article-title>Synthesis and characterization of abietadiene, levopimaradiene, palustradiene, and neoabietadiene: hydrocarbon precursors of the abietane diterpene resin acids</article-title>. <source>Tetrahedron</source>
<year>2001</year>;<volume>57</volume>:<fpage>6155</fpage>&#x02013;<lpage>67</lpage>.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>ZQ</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Fumosorinone, a novel PTP1B inhibitor, activates insulin signaling in insulin-resistance HepG2 cells and shows anti-diabetic effect in diabetic KKAy mice</article-title>. <source>Toxicol Appl Pharmacol</source>
<year>2015</year>;<volume>285</volume>:<fpage>61</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">25796170</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Glucose uptake activities of bis (2, 3-dibromo-4,5-dihydroxybenzyl)ether, a novel marine natural product from <italic>red alga Odonthalia corymbifera</italic> with protein tyrosine phosphatase 1B inhibition, in&#x000a0;vitro and in&#x000a0;vivo</article-title>. <source>PLoS One</source>
<year>2016</year>;<volume>11</volume>:<fpage>e0147748</fpage>.<pub-id pub-id-type="pmid">26808535</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Lipchock</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Brookner</surname><given-names>D</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Uncovering the molecular interactions in the catalytic loop that modulate the conformational dynamics in protein tyrosine phosphatase 1B</article-title>. <source>J Am Chem Soc</source>
<year>2019</year>;<volume>141</volume>:<fpage>12634</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">31339043</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hann</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Oprea</surname><given-names>TI</given-names></name></person-group>
<article-title>Pursuing the leadlikeness concept in pharmaceutical research</article-title>. <source>Curr Opin Chem Biol</source>
<year>2004</year>;<volume>8</volume>:<fpage>255</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">15183323</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jose Ramirez-Espinosa</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yolanda Rios</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Paoli</surname><given-names>P</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of oleanolic acid derivatives: In vitro, in&#x000a0;vivo and in silico studies for PTP-1B inhibition</article-title>. <source>Eur J Med Chem</source>
<year>2014</year>;<volume>87</volume>:<fpage>316</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">25264584</pub-id></mixed-citation></ref></ref-list></back></article>